Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
McKinsey
Mallinckrodt
Merck
AstraZeneca

Last Updated: May 21, 2022

RAPIVAB Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Rapivab, and what generic alternatives are available?

Rapivab is a drug marketed by Biocryst and is included in one NDA. There are three patents protecting this drug.

This drug has sixty-seven patent family members in twenty-eight countries.

The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this compound. Additional details are available on the peramivir profile page.

DrugPatentWatch® Generic Entry Outlook for Rapivab

Rapivab was eligible for patent challenges on December 19, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 16, 2023. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for RAPIVAB
International Patents:67
US Patents:3
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 75
Clinical Trials: 2
Patent Applications: 1,781
Drug Prices: Drug price information for RAPIVAB
What excipients (inactive ingredients) are in RAPIVAB?RAPIVAB excipients list
DailyMed Link:RAPIVAB at DailyMed
Drug patent expirations by year for RAPIVAB
Drug Prices for RAPIVAB

See drug prices for RAPIVAB

DrugPatentWatch® Estimated Generic Entry Opportunity Date for RAPIVAB
Generic Entry Date for RAPIVAB*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RAPIVAB

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
BioCryst PharmaceuticalsPhase 3
Department of Health and Human ServicesPhase 4
Johns Hopkins UniversityPhase 4

See all RAPIVAB clinical trials

US Patents and Regulatory Information for RAPIVAB

RAPIVAB is protected by six US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of RAPIVAB is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting RAPIVAB

Antiviral treatments
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER

Antiviral treatments
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER

Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Antiviral treatments
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER

Antiviral treatments
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS

Antiviral treatments
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for RAPIVAB

See the table below for patents covering RAPIVAB around the world.

Country Patent Number Title Estimated Expiration
South Korea 20160129105 정맥내 항바이러스 치료 (INTRAVENOUS ANTIVIRAL TREATMENTS) See Plans and Pricing
South Korea 102323339 See Plans and Pricing
Germany 69840674 See Plans and Pricing
Australia 2013216632 INTRAVENOUS ANTIVIRAL TREATMENTS See Plans and Pricing
World Intellectual Property Organization (WIPO) 2007117241 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
AstraZeneca
McKinsey
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.